We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Coronavirus Test Works 10 Times Faster

By LabMedica International staff writers
Posted on 14 Apr 2020
Print article
Illustration
Illustration
A new testing method for COVID-19 can confirm the presence of the virus 4-10 times faster than the current method of extracting ribonucleic acid (RNA) molecules from a patient’s swab sample to see whether they contain viral RNA. In addition to being equally accurate, the new test does not use specially produced test kits or reagents needed for extracting RNA and instead uses materials commonly found in diagnostic labs, thus making it significantly cheaper and reducing dependence on imported testing materials.

The new testing method for COVID-19 has been developed by researchers from the Hebrew University of Jerusalem (Jerusalem, Israel). The COVID-19 testing kits currently in use extract RNA molecules from a patient's sample to determine if they have viral RNA within them to confirm the presence of the coronavirus. However, these test kits require testing materials, such as complex reagents to extract the RNA for analysis, which are in short supply globally, thus slowing down the rate of testing and increasing the rate of infection.

The Hebrew University researchers have devised a new COVID-19 testing method using a homemade solution that is more easily available and cheaper than the kits. Instead of complex reagents, their test uses tiny magnetic beads to extract RNA for analysis and can be performed both robotically as well as manually. The beads are also recyclable and can be reused to perform future tests. The method was tested on hundreds of samples and all the tests came out identical to the results obtained using the current test kits. The bead method extracted RNA is also ready for analysis four to 10 times more quickly than most other methods.

The researchers believe if their COVID-19 testing method can help labs significantly eliminate the testing bottleneck by reducing their dependence on external factors. The researchers are now developing a method based on genomic sequencing tools that will allow tens of thousands of samples to be tested simultaneously instead of the current rate of thousands of tests.

Related Links:
The Hebrew University of Jerusalem
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.